High prevalence of inhA promoter mutations among patients with drug-resistant tuberculosis in KwaZulu-Natal, South Africa

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Niehaus, Abraham J ^a   Mlisana, Koleka ^a   Gandhi, Neel R ^b   Mathema, Barun ^c   Brust, James C M ^d  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b EMORY UNIVERSITY   (United States)

^c Department of Medicine   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; RIFAMPICIN; BACTERIAL PROTEIN; CATALASE; INHA PROTEIN, MYCOBACTERIUM; KATG PROTEIN, MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASE; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE; GENE MUTATION; HUMAN; INCIDENCE; INHA GENE; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; PREVALENCE; PROMOTER REGION; SOUTH AFRICA; SPUTUM ANALYSIS; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; MICROBIOLOGY; MUTATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CATALASE; ETHIONAMIDE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; ISONIAZID; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; PREVALENCE; PROMOTER REGIONS, GENETIC; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84947422751     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135003     Document Type: Article

References (20)

1. World Health Organization. Global Tuberculosis Report 2014. Document no WHO/HTM/TB/201408 2014 Geneva.
2. Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011; 38- (3):516-28. doi: 10.1183/09031936.00073611 PMID: 21828024
3. Vilcheze C, Jacobs WR Jr. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol. 2007; 61:35-50. PMID: 18035606
4. Morlock GP, Metchock B, Sikes D, Crawford JT, Cooksey RC. ethA, inhA, and katG loci of ethionamide- resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother. 2003; 47- (12):3799-805. PMID: 14638486
5. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science (New York, NY. 1994; 263(5144):227-30.
6. Guo H, Seet Q, Denkin S, Parsons L, Zhang Y. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol. 2006; 55(Pt 11):1527-31. PMID: 17030912
7. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS medicine. 2009; 6(2):e2. doi: 10.1371/journal.pmed.1000002 PMID: 19209951
8. Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2008; 12(2):139-45. PMID: 18230245
9. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010; 182(5):684-92. doi: 10.1164/rccm.201001-0077OC PMID: 20442432
10. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006; 368(9547):1575-80. PMID: 17084757
11. Conradie F, Meintjes G, Hughes J, Maartens G, Ferreira H, Siwendu S, et al. Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis. S Afr Med J. 2014; 104(3):164-6. PMID: 24897814
12. KwaZulu-Natal Department of Health. 2013/2014 Annual Report; http://www.kznhealth.gov.za/ AnnualReport/2013-2014.pdf (accessed 23 March 2015). 2014.
13. Abate D, Tedla Y, Meressa D, Ameni G. Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2014; 18(8):946-51. doi: 10.5588/ ijtld.13.0926 PMID: 25199009
14. Jagielski T, Bakula Z, Roeske K, Kaminski M, Napiorkowska A, Augustynowicz-Kopec E, et al. Detection of mutations associated with isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates. J Antimicrob Chemother. 2014; 69(9):2369-75. doi: 10.1093/jac/dku161 PMID: 24855126
15. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009; 13(11):1320-30. PMID: 19861002
16. Herrera L, Valverde A, Saiz P, Saez-Nieto JA, Portero JL, Jimenez MS. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical strains isolated in the Philippines. Int J Antimicrob Agents. 2004; 23(6):572-6. PMID: 15194127
17. Varghese B, Shoukri M, Memish Z, Abuljadayel N, Alhakeem R, Alrabiah F, et al. Occurrence of Diverse Mutations in Isoniazid- and Rifampicin-Resistant Mycobacterium tuberculosis Isolates from Autochthonous and Immigrant Populations of Saudi Arabia. Microbial drug resistance. 2014.
18. Muller B, Streicher EM, Hoek KG, Tait M, Trollip A, Bosman ME, et al. inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa? Int J Tuberc Lung Dis. 2011; 15(3):344-51. PMID: 21333101
19. Chihota VN, Muller B, Mlambo CK, Pillay M, Tait M, Streicher EM, et al. Population structure of multiand extensively drug-resistant Mycobacterium tuberculosis strains in South Africa. J Clin Microbiol. 2012; 50(3):995-1002. doi: 10.1128/JCM.05832-11 PMID: 22170931
20. Gandhi NR, Brust JC, Moodley P, Weissman D, Heo M, Ning Y, et al. Minimal diversity of drug-resistant Mycobacterium tuberculosis strains, South Africa. Emerg Infect Dis. 2014; 20(3):426-33. doi: 10.3201/ eid2003.131083 PMID: 24565645